Form 4: Vaxcyte SVP, Finance, Elvia Cowan, Granted Performance Stock Option

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., was granted a performance stock option to purchase 11,900 shares of common stock on November 7, 2024.

Summary

• On November 7, 2024, Elvia Cowan, SVP of Finance at Vaxcyte, Inc., received a performance stock option.
• This option allows her to purchase 11,900 shares of Vaxcyte's common stock at an exercise price of $102.70 per share.
• The option grant was part of a company-wide grant to all eligible employees.
• The option is subject to both service-based and performance-based vesting conditions.
• The service-based vesting occurs in three equal installments on the third, fourth, and fifth anniversaries of the grant date.
• The performance-based vesting requires Vaxcyte's common stock to average at least $154.05 over a one-year period (150% of the grant date closing price).

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice, but the performance-based vesting suggests confidence in the company's future growth.

Positives

• The grant of performance stock options to employees aligns their interests with those of the shareholders, incentivizing them to increase the company's stock price.
• The vesting conditions ensure long-term commitment and performance from the employee.

Risks

• The performance-based vesting condition may not be met if the company's stock price does not reach the required average of $154.05 over a one-year period.
• The employee may leave the company before the service-based vesting is complete, forfeiting a portion of the options.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the performance-based vesting condition suggests an internal expectation or goal for the stock price to reach $154.05.

Industry Context

Stock options are a common form of compensation in the biotechnology industry, used to attract and retain talent while aligning employee incentives with shareholder value. Performance-based vesting adds an extra layer of motivation to achieve specific company goals.

Comparison to Industry Standards

• Many biotech companies use stock options as part of their compensation packages, including companies like Moderna (MRNA) and BioNTech (BNTX).
• The vesting schedules and performance metrics vary widely depending on the company's stage, size, and specific goals.
• The performance target of 150% of the grant date closing price is a fairly aggressive target, suggesting a high level of confidence in the company's future prospects.

Stakeholder Impact

• Shareholders: The performance-based vesting aligns employee incentives with shareholder value, potentially leading to increased stock price.
• Employees: The stock option provides an opportunity for financial gain if the company performs well.
• Company: The stock option helps attract and retain talent.

Key Dates